TherapeuticsMD (TXMD) Reports In-Line Q4 EPS

TherapeuticsMD (NYSE: TXMD) reported Q4 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $5.63 million versus the consensus estimate of $5.33 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Worthington Enterprises raises dividend 5%, adds board member
• Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'